Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: Evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer

被引:89
作者
Cho, Hyunah [1 ]
Lai, Tsz Chung [2 ]
Kwon, Glen S. [1 ]
机构
[1] Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, Madison, WI 53705 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA
基金
美国国家卫生研究院;
关键词
Bioluminescence imaging; Combination drug delivery; Ovarian cancer; Paclitaxel; PET imaging; Polymeric micelles; RESISTANCE; EFFICACY; THERAPY; CELLS; CHEMOTHERAPY; INHIBITION; SYSTEM;
D O I
10.1016/j.jconrel.2012.12.005
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Ovarian cancer is the most lethal gynecological malignancy, characterized by a high rate of chemoresistance. Current treatment strategies for ovarian cancer focus on novel drug combinations of cytotoxic agents and molecular targeted agents or novel drug delivery strategies that often involve intraperitoneal (IP) injection. Poly( ethylene glycol)-block-poly(epsilon-caprolactone) (PEG-b-PCL) micelles were loaded with paclitaxel (cytotoxic agent), cyclopamine (hedgehog inhibitor), and gossypol (BcI-2 inhibitor). After physicochemical studies focusing on combination drug solubilization, 3-drug PEG-b-PCL micelles were evaluated in vitro in 2-D and 3-D cell culture and in vivo in xenograft models of ovarian cancer, tracking bioluminescence signals from ES-2 and SKOV3 human ovarian cancer cell lines after IP injection. 3-Drug PEG-b-PCL micelles were not significantly more potent in 2-D cell culture in comparison to paclitaxel; however, they disaggregated ES-2 tumor spheroids, whereas single drugs or 2-drug combinations only slowed growth of ES-2 tumor spheroids or had no noticeable effects. In ES-2 and SKOV3 xenograft models, 3-drug PEG-b-PCL micelles had significantly less tumor burden than paditaxel based on bioluminescence imaging, 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) PET imaging, and overall survival. F-18-FLT-PET images clearly showed that 3-drug PEG-b-PCL micelles dramatically reduce tumor volumes over paclitaxel and vehicle controls. In summary, PEG-b-PCL micelles enable the IP combination drug delivery of paditaxel, cyclopamine and gossypol, resulting in tumor growth inhibition and prolonged survival over paditaxel alone. These results validate a novel treatment strategy for ovarian cancer based on drug combinations of cytotoxic agents and molecular targeted agents, delivered concurrently by a nanoscale drug delivery system, e.g. PEG-b-PCL micelles. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 33 条
[1]   18F-FLT PET as a Surrogate Marker of Drug Efficacy During mTOR Inhibition by Everolimus in a Preclinical Cisplatin-Resistant Ovarian Tumor Model [J].
Aide, Nicolas ;
Kinross, Kathryn ;
Cullinane, Carleen ;
Roselt, Peter ;
Waldeck, Kelly ;
Neels, Oliver ;
Dorow, Donna ;
McArthur, Grant ;
Hicks, Rodney J. .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (10) :1559-1564
[2]   Drug Delivery Systems for Intraperitoneal Therapy [J].
Bajaj, Gaurav ;
Yeo, Yoon .
PHARMACEUTICAL RESEARCH, 2010, 27 (05) :735-738
[3]  
Barbolina MV, 2009, CANCER TREAT RES, V149, P319, DOI 10.1007/978-0-387-98094-2_15
[4]   The Changing View of High-Grade Serous Ovarian Cancer [J].
Berns, Els M. J. J. ;
Bowtell, David D. .
CANCER RESEARCH, 2012, 72 (11) :2701-2704
[5]   Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened [J].
Chen, JK ;
Taipale, J ;
Cooper, MK ;
Beachy, PA .
GENES & DEVELOPMENT, 2002, 16 (21) :2743-2748
[6]   Polymeric Micelles for Neoadjuvant Cancer Therapy and Tumor-Primed Optical Imaging [J].
Cho, Hyunah ;
Kwon, Glen S. .
ACS NANO, 2011, 5 (11) :8721-8729
[7]   Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer [J].
De Souza, Raquel ;
Zahedi, Payam ;
Badame, Rose M. ;
Allen, Christine ;
Piquette-Miller, Micheline .
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (07) :1289-1299
[8]   Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles [J].
Devalapally, Harikrishna ;
Duan, Zhenfeng ;
Seiden, Michael V. ;
Amiji, Mansoor M. .
CLINICAL CANCER RESEARCH, 2008, 14 (10) :3193-3203
[9]   Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer [J].
Devalapally, Harikrishna ;
Duan, Zhenfeng ;
Seiden, Michael V. ;
Amiji, Mansoor M. .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (08) :1830-1838
[10]   Optical small animal imaging in the drug discovery process [J].
Dufort, S. ;
Sancey, L. ;
Wenk, C. ;
Josserand, V. ;
Coll, J. L. .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2010, 1798 (12) :2266-2273